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Abstract
Background and objective: Fractional exhaled nitric oxide (FeNO) is a non-invasive
biomarker that reflects IL-4/IL-13 production and therefore represents T2 allergic
inflammation. FeNO has previously been used to guide inhaled corticosteroid (ICS)
treatment in asthma. The purpose of this study was to determine if a low FeNO
(≤27 ppb) could be used to reliably identify patients with symptoms suggestive of
asthma who would not benefit from initiating treatment with an ICS.
Methods: A total of 180 steroid-naïve adults with healthcare professional suspected
asthma and an FeNO of ≤27 ppb were randomized to receive either 400 mcg of
budesonide or placebo daily for 3 months. The primary outcome was the difference in
the Asthma Control Questionnaire 7 (ACQ7) between treatment groups and the study
was powered to determine equivalence. Secondary outcomes were the difference in
FEV1, Medical Research Council and Leicester Cough Questionnaire scores.
Results: One hundred and thirty-four patients (68 budesonide and 66 placebo) com-
pleted the study and were included in the analysis. The between-group mean differ-
ence in ACQ7 from baseline to the end of the study was −0.25 and the 95% CI
around this difference was −0.004 to 0.495 confirming equivalence (p < 0.05). Differ-
ences in forced expiratory volume over 1 s and other secondary outcomes were also
small and clinically unimportant.
Conclusion: The results of this study suggest that steroid-naïve patients with symp-
toms suggestive of asthma and an FeNO ≤ 27 ppb are unlikely to benefit from initiat-
ing treatment with an ICS over 3 months. However, further research is recommended
to confirm these findings before withholding ICS treatment.
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INTRODUCTION
Asthma is a common chronic inflammatory airway disease
that is often over-diagnosed1 due to the non-specific nature
of the typical symptoms including cough, wheeze, chest tight-
ness and shortness of breath. Inhaled corticosteroid (ICS)
treatment is now recommended for all but the mildest cases of
asthma meaning many patients are prescribed medication they
do not require and, as such, are at risk of developing unneces-
sary side effects such as oral candidiasis or dysphonia. A simple
test that could be used to guide clinicians in prescribing or not
prescribing therapeutic interventions, following the treatable
traits concept,2 could improve patient care and help to reduce
unnecessary healthcare costs.
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Fractional exhaled nitric oxide (FeNO) is a non-invasive
biomarker produced in bronchial epithelial cells that reflects
IL-4/IL-13 production and is, therefore, a proxy marker of
T2 allergic inflammation in the airways.3,4 Elevated FeNO
levels have been used to identify patients with T2 high air-
way inflammation who are likely to respond to an ICS,5 and
we have previously shown in an open-label study that an
FeNO level less than 27 parts per billion (ppb) is highly pre-
dictive of a negative response to ICS treatment.6 In the cur-
rent study, patients with symptoms suggestive of asthma
and an FeNO ≤ 27 ppb were randomized to receive either
an ICS or placebo for 3 months to determine if a low FeNO
level could be used to reliably identify patients who are
unlikely to benefit from initiating treatment with an ICS in
the short term.
METHODS
Study design and participants
This 12-week randomized, double-blind, placebo-controlled,
single-centre study recruited participants aged 18 years and
over from primary care practices in and around Nottingham
and from poster advertisements between May 2016 and
March 2018. Primary care practice registries were screened
for patients with healthcare professional suspected asthma
who were using a short-acting beta-agonist (SABA) as
required as their only asthma-related medication. To enter
the study, patients must have had symptoms that required
them to use their SABA no less than monthly. All partici-
pants were also required to have a prebronchodilator forced
expiratory volume over 1 s (FEV1) > 70% predicted and an
FeNO ≤ 27 ppb (mean of two consecutive measurements).
Participants were excluded from the study if they had
received any asthma medications other than a SABA within
the previous 6 months, had any significant co-morbidities,
had a hypersensitivity to budesonide or its excipients, as well
as any pregnant or breastfeeding mothers. Participants iden-
tified via screening were contacted by phone by one of the
study team and invited to attend a study visit at their general
practioner (GP) surgery or at the Nottingham Respiratory
Research Unit, where written informed consent was
obtained before any study related procedures.
Study protocol
Participants were randomized to receive either 200 mcg
budesonide (Pulmicort) via a Turbuhaler (AstraZeneca) or
placebo inhaler identical in shape, colour and appearance
(AstraZeneca) one puff twice-daily for 12 weeks. Study
inhalers were stored in a secure locker in the Clinical Trials
Pharmacy at Nottingham City Hospital and were dispensed
by authorized pharmacy personnel. Randomization was
conducted in blocks of eight according to smoking status:
current (or smoked within the past 12 months) or never/ex
(never or quit more than 12 months ago). Randomization
sequences were generated by the Respiratory Research Unit
using an online pseudo-random number generator service
(sealedenvelope.com).
During the randomization visit, a medical history was
recorded and an average of two FeNO readings was obtained
consecutively. Participants with an FeNO ≤ 27 ppb also com-
pleted the Asthma Control Questionnaire 7 (ACQ7),7 Leicester
Cough Questionnaire (LCQ)8 and Medical Research Council
(MRC) dyspnoea questionnaires.9 The ACQ7 consisted of
seven questions, overall scores were obtained by averaging the
score from each question, a change of ≥0.5 was required for
the difference to be considered clinically significant.10 The
LCQ consisted of 19 questions encompassing three domains,
the final score was the sum of each domain score which was
determined by adding together the scores of the questions in
each domain and dividing by the number of questions in that
domain. The possible scores ranged from 3 to 21, where 3 rep-
resented the worst cough and 21 no cough and an increase of
≥1.3 was required for the difference to be considered clinically
significant.11 The MRC consisted of five questions alongside a
1–5 stage scale to ascertain the grade of perceived clinical
breathlessness on activity. Stage 1 represented no breathless-
ness while stage 5 represented a disabling level of breathless-
ness.9 There is no accepted interval of change that represents a
clinically significant improvement for this test.
FeNO was performed at a constant flow rate of 50 mL/s
(NIOX VERO®; Aerocrine, Solna, Sweden) followed by spi-
rometry, performed according to the British Thoracic Society
(BTS) criteria using either Carefusion or Vitalograph spirom-
eters.12 Venepuncture was conducted on participants if sched-
uled transport could be arranged to get the sample to a
pathology department for a full blood count the same day.
Finally, participants were instructed on the correct use of the
Turbuhaler. Participants were seen for follow-up visits every
4 weeks for 12 weeks during which FeNO, spirometry and
questionnaires were repeated, and at each visit were asked
about their medication adherence.
Information storage
Clinical information obtained during the study visits from
the research nurses was recorded in the participants case
report form and then stored in the online database Medrio.
SUMMARY AT A GLANCE
We conducted a randomized, double-blind placebo-
controlled trial and demonstrated that steroid-naïve
patients with symptoms suggestive of asthma and a
fractional exhaled nitric oxide level ≤ 27 parts per
billion (ppb) are unlikely to benefit from treatment
with an inhaled corticosteroid over 3 months.
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Outcome measures
The primary outcome was the mean difference in change in
ACQ7 score over the 12-week period between the budesonide
and placebo groups. Secondary outcomes included the mean
difference in the change in FEV1, MRC and LCQ scores
between the two groups and the number of ACQ7, FEV1 and
LCQ responders (defined as decrease of ≥0.5 points, an
increase of ≥200 ml and decrease of ≥1.3 points, respectively)
over 12 weeks within each group over 12 weeks.
Statistical analysis
It was determined that 150 patients would be required to
give 90% power to demonstrate equivalence based on a dif-
ference in ACQ7 of ≥0.5 being clinically important and an
SD of 0.9.6 The initial goal was to recruit 165 patients to
allow for drop-outs but this figure was subsequently
increased to 180 due to more drop-outs than expected. All
patients who completed the 12 weeks were included in the
final analysis.
All analysis was conducted in Stata/SE 15.0 (2017;
StataCorp, TX). Minitab (2010; Minitab Inc., PA) was used
to generate the equivalence graph. Results are given in mean
and SD where the data were normally distributed. In cases
where the data were not normally distributed, the median
and interquartile range are given.
Statistical analysis of equivalence of the primary out-
come was assessed using a two, one-sided equivalence test
(TOST) as the null hypothesis was that there would not
be a difference between the treatment groups. The TOST
was conducted with a minimal clinically significant differ-
ence (δ) of 0.5 in ACQ score,13–15 and a type 1 error rate
of 0.05. TOSTs were also conducted for the secondary
outcomes LCQ and FEV1, δ 1.3 and δ 0.2 L, respectively.
The secondary outcomes were assessed within tertiles
of FeNO levels using chi-square and unpaired t-tests to
evaluate how differences between responders and non-
responders in the budesonide and placebo groups change
with FeNO.
RESULTS
A total of 4700 patients were contacted. Of these,
236 responded and were screened with 180 randomized.
Forty-six participants failed to complete all visits, 23 from
each group. In total, 134 patients completed all study visits
and were included in the analysis. A post hoc calculation
indicated 84% power at alpha 0.05 for equivalence of
primary outcome (Figure 1).
F I G U R E 1 Study flow diagram
LOW FeNO AND ICS IN SUSPECTED ASTHMA 3
Baseline characteristics
The baseline demographics and clinical characteristics for
all 180 participants who were randomized and completed
visit 1 are presented in Table 1. Participants were well
matched between the groups at baseline. The majority of
patients were female (70% and 74%), non-smokers (78%
and 80%) and Caucasian (88% and 88%) in the budesonide
and placebo groups, respectively.
Primary outcome
The mean changes in ACQ7 score were 0.53 (SD ±0.79) and
0.29 (SD ±0.95) in the budesonide and placebo groups,
respectively. The between-group mean difference in ACQ7
was −0.25 with 95% CI of −0.004 to 0.495 which fell within
the equivalence interval of −0.5 to 0.5, demonstrating equiv-
alence (p < 0.001, p = 0.047) (Figure 2). A total of 53 partici-
pants, 29 (42%) in the budesonide and 24 (36%) in the
placebo group, had an improvement in ACQ7 of ≥0.5 fol-
lowing 12 weeks of treatment (p = 0.4).
Secondary outcomes
Mean FEV1 values decreased from 2.92 to 2.90 L in the
budesonide group and remained at 2.69 L throughout the
study in the placebo group. The between-group mean differ-
ence in FEV1 was 0.01 with 95% CI of −0.06 to 0.06 which
fell within the equivalence interval of −0.2 to 0.2, demon-
strating equivalence (p < 0.001, p < 0.001). Following
12 weeks, 13 (10%) participants had a significant improve-
ment in FEV1 of ≥200 ml, four of them also had a ≥12%
increase in FEV1 % predicted. Of these, nine (13%) were in
the budesonide group and four (6%) were in the placebo
group (p = 0.161).
LCQ increased by 1.85 and 1.97 points in the
budesonide and placebo groups, respectively, throughout
the study. The between-group mean difference in LCQ was
−0.12 with 95% CI of −1.06 to 1.31 which fell just outside
the equivalence interval of −1.3 to 1.3 (p = 0.02, p = 0.05). A
total of 57 participants, 27 (40%) and 30 (45%) in the
budesonide and placebo groups, respectively, had a signifi-
cant improvement in LCQ of ≥1.3 (p = 0.501).
Twenty-two (32%) and 19 (30%) of participants had an
improvement in MRC score in the budesonide and placebo
T A B L E 1 Baseline demographics
Variable
Budesonide Placebo
n = 91 n = 89
Age (years), mean (SD) 42.40 (17.82) 45.80 (18.20)
BMI, kg/m2, median
(IQR)




1.30 (0.20–84.00) 2.00 (0.20–89.00)
Sex – female, n (%) 64.00 (70) 66.00 (74)
Ethnicity, n (%)
Caucasian 80 (88) 78 (88)
Asian 2 (2) 3 (3)
Black 2 (2) 5 (6)
Other 7 (8) 3 (3)
Smoking status, n (%)
Never 71 (78) 72 (80)
Current 20 (21) 17 (20)
Presenting symptoms, n (%)
Cough 74.00 (83) 69.00 (80)
Wheeze 58.00 (65) 62.00 (69)
SOB 65.00 (73) 69.00 (80)
Questionnaires, median (IQR)
ACQ7 1.28 (0.85–2.00) 1.28 (0.57–1.86)
LCQ 17.46 (12.93–20.07) 17.36 (13.43–19.96)
MRC 2.00 (1.00–2.00) 2.00 (1.00–2.00)
Lung function
FEV1 (L), mean (SD) 3.02 (0.78) 2.73 (0.72)
FEV1 % predicted,
mean (SD)
95.00 (13.79) 93.11 (14.74)
FVC (L), mean (SD) 3.81 (20.91) 3.52 (0.87)
FEV1/FVC, mean (SD) 79.24 (8.20) 77.41 (8.50)








Abbreviations: ACQ, Asthma Control Questionnaire; FeNO, fractional exhaled nitric
oxide; FEV1, forced expiratory volume over 1 s; FVC, forced vital capacity; IQR,
interquartile range; LCQ, Leicester Cough Questionnaire; MRC, Medical Research
Council; ppb, parts per billion; SOB, shortness of breath.
F I G UR E 2 Two, one-sided equivalence test Asthma Control
Questionnaire 7 mean difference and 95% CI (−0.495 to 0.004) showing the
upper and lower equivalence interval (≤0.01, p = 0.04). LEL, lower
equivalence limit; UEL, upper equivalence limit
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groups with mean changes of 0.30 and 0.23, respectively
(between-group mean difference 0.67; p = 0.52).
Baseline FeNO levels and response to treatment
A post hoc analysis was performed on baseline FeNO
levels divided into tertile subgroups (low, ≤5–12 ppb;
moderate, >12–20 ppb; and high, >20–27 ppb) to deter-
mine if there was a relationship with response to treat-
ment (ACQ7). The number of responders in the low
and moderate subgroups were independent of treatment
(χ2 p = 0.15 and χ2 p = 0.81, respectively). Statistical sig-
nificance was observed in the number of responders
within the higher FeNO subgroup, suggesting the differ-
ence may be dependent on treatment when FeNO is greater
than 20 ppb (63.6% budesonide, 20.0% placebo; χ2
p = 0.0043) (Figure 3). Mean baseline ACQ7 scores and
blood eosinophil levels were similar between treatment
groups within FeNO subgroups (Table 2). The maximum
FeNO level observed increased to 66.5 and 73 ppb in the
budesonide and placebo groups, respectively, by the end of
the study. However, the median values remained similar
(17–16.75 ppb in the budesonide group and 15–17.50 ppb
in the placebo group).
DISCUSSION
This study demonstrated that the between-group mean dif-
ference in ACQ7 and FEV1 fell within their respective equiv-
alence intervals suggesting that initiating treatment with an
ICS in steroid-naïve patients with symptoms suggestive of
asthma, FeNO ≤ 27 ppb and FEV1 > 70% predicted is
equivalent to treatment with placebo over 12 weeks.
Mean differences in LCQ and MRC were also very similar
between groups, although LCQ was marginally outside of
the equivalence interval, favouring placebo. This finding
builds on our previous findings which determined that base-
line FeNO levels ≤ 27 ppb had a negative predictive value of
93% to starting ICS treatment.6
As there is no definite test to diagnose or exclude
asthma, or to determine which treatments will be benefi-
cial, the decision to initiate corticosteroids is typically
driven by a compatible history with or without objective
evidence of airflow obstruction. This is not ideal as symp-
toms are non-specific and do not necessarily reflect the
type or severity of inflammation in the airways,16,17 and
spirometry is often normal when patients are asymptom-
atic. Several studies have shown that asthma is over-
diagnosed,1 and there is growing evidence that up to
25%–35% of patients with confirmed asthma do not
benefit from ICS treatment.18,19 FeNO is non-invasive, easy
to perform, requires minimal effort and provides almost
immediate results. As such, FeNO has the potential to facil-
itate treatment decisions by identifying patients who are
unlikely to benefit from initiating an ICS.
Numerous studies have evaluated the utility of FeNO to
predict response to corticosteroids. Smith et al. determined
that regardless of the patient’s diagnosis, those with an
FeNO level > 47 ppb had a greater response to ICS than
patients with low FeNO levels (<15 ppb).20 Hahn et al.
determined that patients with chronic cough and an FeNO
of >35 ppb were more likely to respond to an ICS than
patients with an FeNO < 35 ppb21 and Martin et al. deter-
mined that the optimal FeNO cut-off point to predict ICS
response was >33 ppb.6 Therefore, although the cut-off
points for high, moderate and low FeNO levels vary between
studies, it has been well documented that higher FeNO
levels are predictive of a positive response to an ICS.22 To
our knowledge, this is the first study to demonstrate that
people with suspected asthma and a low FeNO (≤27 ppb)
F I G U R E 3 Response to intervention according to baseline fractional
exhaled nitric oxide tertiles. Budesonide , Placebo
T A B L E 2 Baseline features based on FeNO tertiles
FeNO (5–12) FeNO (>12–20) FeNO (>20–27)
Budesonide Placebo p Budesonide Placebo p Budesonide Placebo p
Total 23 17 23 29 22 20
Responders (%) 7 (30.4) 9 (52.9) 0.151 8 (34.8) 11 (37.9) 0.815 14 (63.6) 4 (20.0) 0.004
Mean ACQ7 (SD) 1.73 (1.04) 1.76 (1.12) 0.924 1.31 (0.83) 1.23 (0.93) 0.738 1.31 (0.81) 1.24 (0.74) 0.757
Mean eosinophils (SD) 0.13 (0.12) 0.28 (0.21) 0.024 0.15 (0.12) 0.15 (0.09) 0.974 0.24 (0.13) 0.27 (0.17) 0.616
Abbreviations: ACQ7, Asthma Control Questionnaire 7; FeNO, fractional exhaled nitric oxide.
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do not receive a short-term benefit to initiating treatment
with an ICS.
When considering the clinical implications of our find-
ings, it is important to recognize that we did not study
patients with confirmed asthma and a low FeNO, but
patients presenting with symptoms considered by a
healthcare professional to be suggestive of asthma. We
have therefore studied a group of patients with symptoms
caused by a mixture of mild asthma and other problems.
We are not, therefore, suggesting that a low FeNO iden-
tifies a group of steroid non-responsive asthma patients
but a group of patients who either do not have asthma or
have steroid non-responsive asthma. It is also possible that
the latter group could still benefit from an ICS in terms of
exacerbation prevention if studied over a longer time
period as shown previously.23 Therefore, we suggest that
patients with symptoms suggestive of asthma and an
FeNO ≤ 27 ppb and especially those with an
FeNO < 20 ppb should undergo further investigation to
confirm or dispute the diagnosis of asthma, ideally before
starting an ICS. If these further investigations support a
diagnosis of asthma, then ICS treatment is probably still
indicated to prevent asthma exacerbations, something
which may be best achieved by using a combination of
bronchodilator with ICS as required, rather than regular
ICS, as recommended in Golbal Initiative For Asthma
(GINA) 2019.22 This approach overcomes poor adherence
with regular ICS which is likely to be common in patients
who obtain no symptomatic benefit as shown in this
study.
Our study has several limitations which also need to be
considered. First, we had a low response rate from our invi-
tation to take part. This is a common finding in clinical
studies but it does raise the possibility that we have studied
a population not typical of the overall population of interest
and which could have introduced bias into our findings. For
example, 20% of our population were smokers and smoking
is known to lower FeNO levels. Second, we had no formal
way of assessing adherence with the inhaled medication,
although participants were asked about this at each visit.
Corticosteroids are known to suppress FeNO and this has
previously been used to assess treatment adherence.23 In this
study, we noted a general increase in FeNO throughout the
study. This could suggest poor adherence in some partici-
pants and could be a reason why some participants failed
to respond; however, this could also represent a regression
to the mean, as the study population was at the bottom end
of the possible values at baseline. Third, difficulties in
transporting blood samples from primary care clinics back
to the laboratory for processing in a timely manner resulted
in baseline blood eosinophil levels only being determined
for 115 participants, 92 of whom completed all study visits.
Finally, FeNO is affected by many individual factors such as
age, height and gender as well as external factors such as cig-
arette smoking, nitrate-rich foods, allergens, viral infections,
exercise and air pollution.5 As such, FeNO readings taken at
one point in time may not accurately reflect airway
inflammation throughout the year and longitudinal changes
also need to be performed.
Our findings demonstrate that, in steroid-naïve patients
with symptoms suggestive of asthma, FeNO levels ≤ 27 ppb
and FEV1 > 70% predicted, ICSs are no more effective than
placebo over 3 months. Such patients are likely to benefit
from further investigation rather than simply initiating
treatment with an ICS, but further research is needed to
confirm these findings.
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